

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Rainmed Medical Limited

潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2297)

**RESIGNATION OF EXECUTIVE DIRECTORS,
CHIEF EXECUTIVE OFFICER AND VICE PRESIDENT;
APPOINTMENT OF EXECUTIVE DIRECTORS AND
JOINT CHIEF EXECUTIVE OFFICER; APPOINTMENT
OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE,
REMUNERATION COMMITTEE AND NOMINATION
COMMITTEE; RE-COMPLIANCE WITH THE LISTING
RULES**

This announcement is made by Rainmed Medical Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

**RESIGNATION OF EXECUTIVE DIRECTORS, CHIEF EXECUTIVE OFFICER
AND VICE PRESIDENT**

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that (i) Mr. Huo Yunfei (霍雲飛) (“**Mr. Huo**”) has resigned as a chief executive officer of the Company and ceased to be the chairman of the nomination committee of the Company due to the internal management adjustment with effect from July 15, 2025, (ii) Mr. Lyu Yonghui (呂永輝) (“**Mr. Lyu**”) has resigned as an executive Director due to the internal management adjustment with effect from July 15, 2025, and (iii) Ms. Gu Yang (谷陽) (“**Ms. Gu**”) has resigned as an executive Director and vice president of the Company and has ceased to be a member of the remuneration committee of the Company (“the **Remuneration Committee**”) due to her intension to pursue with her other commitments and the need to devote more time for her family with effect from July 15, 2025 (together, the “**Resignations**”). Upon the Resignations, (i) Mr. Huo will remain as the chairman of the Board, executive Director and authorized representative of the Company under Rule 3.05 of the Listing Rules, and (ii) Mr. Lyu will remain as the joint chief executive officer.

Each of Mr. Huo, Mr. Lyu and Ms. Gu has confirmed that he/she has no disagreement with the Board and there is no matter in relation to his/her resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Huo, Mr. Lyu and Ms. Gu for their valuable contributions to the Group during their tenure of office of respective positions in the Company.

APPOINTMENT OF EXECUTIVE DIRECTORS AND JOINT CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Mr. Zhu Zeke (朱則柯) (“**Mr. Zhu**”) has been appointed as an executive Director and joint chief executive officer with effect from July 15, 2025 and Ms. Duan Jing (段靜) (“**Ms. Duan**”) as an executive Director with effect from July 15, 2025.

The biographical details of Mr. Zhu and Ms. Duan are set out below:

Mr. Zhu Zeke, aged 41, joined the Group in July 2025 as an executive Director and joint chief executive officer. He obtained his bachelor degree of art major in English from Beijing International Studies University (北京第二外國語學院) in July 2010 in the PRC. He further obtained the Level 3 certificate of the China Accreditation Test For Translators and Interpreters (CATTI).

Prior to his joining in the Group, He served as the chairman of the board for Beijing Ambrey Technology Co., Ltd. (北京安布瑞科技有限公司), a company primarily engaged in technology promotion and health services, since March 2019 where he was primarily responsible for strategic development and other business areas. Since March 2020, he became the executive partner of Beijing Cabest Enterprise Management Center (Limited Partnership) (北京卡貝斯特企業管理中心 (有限合夥)) and was primarily responsible for overseeing the investment of the entity. He also served as senior management role for other companies previously.

As of the date of this announcement, Mr. Zhu is a substantial shareholder of the Company. He indirectly, through Apsara Technology Limited, holds 233,559,800 shares of the Company, representing approximately 16.67% equity interest of the Company.

Ms. Duan Jing, aged 41, joined the Group in April 2020 as an human resource (HR) manager and was further promoted as the director for HR department. She obtained her bachelor’s degree in law from Jiangnan University (江漢大學) in June 2006 in the PRC and further pursued master’s degree in applied psychology (with a focus on human resources) in South China Normal University (華南師範大學) in 2008 in the PRC.

Prior to her joining in the Group, she worked in Suzhou Mediston Medical Technology Co., Ltd. (蘇州麥迪斯頓醫療科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603990) and primarily engaged in clinical information systems and digital operating rooms since July 2016, where she served as the manager of the HR department, a senior HR business partner, and the head of organizational development, responsible for various HR matters within the group. From 2012 to 2015, she was the HR supervisor for the South China branch of ASC Fine Wines (Shanghai) Co., Ltd. (ASC精品酒業(上海)有限公司) (the wine importer for Suntory Group in the PRC), and was primarily responsible for overseeing HR operations and key projects in South China and the Hong Kong-Macau region. From 2007 to 2012, she served as the HR supervisor at Crocs (Shenzhen) Co., Ltd. (卡駱馳鞋業(深圳)有限公司) (NASDAQ Stock Code: CROX) and was primarily responsible for daily HR operations and HR projects in the Asia-Pacific region.

As of the date of this announcement, 280,000 share options under the pre-IPO share option scheme adopted by the Company on December 10, 2021 has been granted to Ms. Duan, which is yet to be exercised.

Each of Mr. Zhu and Ms. Duan will hold office until the next annual general meeting of the Company, and will then be eligible for re-election at such meeting. The term of each of Mr. Zhu and Ms. Duan's service as a Director is subject to retirement by rotation and re-election at the annual general meeting of the Company. Each of Mr. Zhu and Ms. Duan will be appointed for a term of three years, which will continue thereafter until terminated by either party giving not less than one month's prior notice. Each of Mr. Zhu and Ms. Duan has entered into a service contract with the Company for a term of three years commencing on July 15, 2025. Each of Mr. Zhu and Ms. Duan is not entitled to any director's fee.

As at the date of this announcement, save as disclosed above, (i) each of Mr. Zhu and Ms. Duan does not have any other interests or short positions in any Shares (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")); (ii) each of Mr. Zhu and Ms. Duan has not held any directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years, and any other major appointments and professional qualifications; (iii) each of Mr. Zhu and Ms. Duan does not have any other relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined under the Listing Rules); and (iv) each of Mr. Zhu and Ms. Duan does not hold any other position in the Company and/or its subsidiaries.

Further, since Mr. Huo no longer served as the chief executive officer of the Company, the Company has complied with C.2.1 of Part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules which requires the roles of chairman and chief executive should be separate and should not be performed by the same individual.

Save as disclosed herein, there are no other matters concerning each of Mr. Zhu and Ms. Duan's appointment that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to extend a warm welcome to Mr. Zhu and Ms. Duan in joining the Company and/or the Board.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Zhao Hui (趙暉) (“**Mr. Zhao**”) has been appointed as an independent non-executive Director with effect from July 15, 2025.

The biographical details of Mr. Zhao are set out below:

Mr. Zhao Hui (趙暉), aged 47, joined the Group on July 15, 2025 as an independent non-executive Director.

From August 2002 to February 2009, Mr. Zhao worked at the PricewaterhouseCoopers Zhongtian (Special General Partnership), Guangzhou Branch (普華永道中天會計師事務所(特殊普通合夥)廣州分所), served as an audit associate and later becoming a deputy manager. From February 2009 to July 2012, he served as the chief financial officer at Guangzhou Tuoo Consulting Co., Ltd. (廣州拓歐諮詢有限公司). From July 2012 to December 2014, Mr. Zhao was a chief financial officer at Guangzhou Huiqin Investment Consulting Co., Ltd. (廣州匯勤投資諮詢有限公司). He served as a Senior Manager at the PricewaterhouseCoopers Zhongtian (Special General Partnership), Guangzhou Branch (普華永道中天會計師事務所(特殊普通合夥)廣州分所), from January 2015 to September 2020. From October 2020 to September 2021, he served as the chief financial officer at Dexin Service Group Co., Ltd. (德信服務集團有限公司), which is a company listed on the Hong Kong Stock Exchange (stock code: 2215.HK), where he managed the group’s financial operations and helped advance its strategic business goals. Since October 2021, Mr. Zhao has been a partner at Guangzhou Huiqin Investment Consulting Co., Ltd. (廣州匯勤投資諮詢有限公司), focusing on investment and financing projects. Since November 2024, he has also been serving as a non-executive director at Xinji Shaxi Group Co., Ltd. (信基沙溪集團股份有限公司), which is a company listed on the Hong Kong Stock Exchange (stock code: 3603.HK), a company specializing in the operation of a hotel supplies marketplace.

Mr. Zhao obtained a bachelor’s degree in science in June 2001 and a bachelor’s degree in administration from Sun Yat-sen University (中山大學) in June 2002 in the PRC. In May 2011, Mr. Zhao obtained the qualification of Intermediate Accountant (中級會計師) from the Guangdong Provincial Department of Human Resources and Social Security (廣東省人力資源和社會保障廳). In November 2013, he obtained the qualification of International Certified Internal Auditor (國際註冊內部審計師), certified by the International Internal Auditors Association and awarded by the China Internal Audit Association (中國內部審計協會). In April 2014, he obtained the qualification of Certified Public Accountant (註冊會計師) from the Chinese Institute of Certified Public Accountants (中國註冊會計師協會).

Mr. Zhao has entered into an appointment letter with the Company for a term commencing from July 15, 2025 until the next annual general meeting of the Company, upon which Mr. Zhao shall be eligible for re-election by the shareholders of the Company. Thereafter, Mr. Zhao will be subject to retirement by rotation and re-election in accordance with the memorandum and articles of association of the Company. Mr. Zhao is entitled to a director's fee of HK\$280,000 per annum. The emolument of Mr. Zhao has been determined by the Board with reference to the prevailing market conditions, his experience, his roles and responsibilities and the Company's remuneration policy. Such remuneration has been recommended by the Remuneration Committee and approved by the Board.

As at the date of this announcement, save as disclosed above, (i) Mr. Zhao does not have any interests or short positions in any shares of the Company (within the meaning of Part XV of the SFO); (ii) Mr. Zhao has not held any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) Mr. Zhao does not have any relationship with any Directors, senior management or substantial shareholders of the Company (as defined under the Listing Rules); and (iv) Mr. Zhao does not hold any other position in the Company and/or its subsidiaries.

Mr. Zhao has confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules. Save as disclosed above, there is no other matter relating to his appointment as an independent non-executive Director that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange, and there is no other information that need to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Zhao for joining the Board.

CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION COMMITTEE

The Board further announces that, with effect from July 15, 2025, following the Resignations and the appointment of Mr. Zhu, Ms. Duan and Mr. Zhao, the composition of the Board committees has been changed as follows:

Audit Committee	Mr. Liu Shuen Kong (廖船江) (<i>Chairman</i>) Mr. Chen Xuefeng (陳雪峰) Mr. Zhao Hui (趙暉)
Remuneration Committee	Mr. Chen Xuefeng (陳雪峰) (<i>Chairman</i>) Ms. Duan Jing (段靜) Mr. Liu Shuen Kong (廖船江)
Nomination Committee	Mr. Zhao Hui (趙暉) (<i>Chairman</i>) Ms. Duan Jing (段靜) Mr. Liu Shuen Kong (廖船江)

RE-COMPLIANCE WITH THE LISTING RULES

Reference is made to the announcement of the Company dated June 13, 2025 in relation to, among other things, the resignation of the independent non-executive Director. Following the appointment of Mr. Zhao and the change in composition of the Board committees, the Company has re-complied with requirement of Rules 3.10(1), 3.10A, 3.21, 3.25 and 3.27A of the Listing Rules.

By Order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, July 15, 2025

As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Zhu Zeke and Ms. Duan Jing as executive Directors, Dr. Huo Yunlong, Mr. Wang Lin and Mr. Heng Lei as non-executive Directors, and Mr. Liu Shuen Kong, Mr. Chen Xuefeng and Mr. Zhao Hui as independent non-executive Directors.